Myriad Genetics posts Q1 2026 revenue growth, launches new cancer test, and confirms 2026 guidance

Myriad Genetics reported Q1 2026 revenue of $200.4 million, up 2% year-over-year, driven by growth in Cancer Care Continuum and Mental Health testing despite a decline in Prenatal Health. The company launched its Precise Molecular Residual Disease (MRD) assay and received FDA approval for the MyChoice CDx test as a companion diagnostic for ovarian cancer treatment. While reporting a GAAP net loss of $34.1 million, Myriad reaffirmed its full-year 2026 revenue guidance of $860-$880 million, expecting stronger second-half performance. The company is advancing new product launches, including an AI-enabled prostate cancer test, positioning for growth in 2027 and beyond.